|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Outcome of non-variceal acute upper gastrointestinal bleeding in relation to the time of endoscopy and the experience of the endoscopist: A two-year survey显示文摘AIM: To prospectively assess the impact of time of endoscopy and endoscopist's experience on the outcome of non-variceal acute upper gastrointestinal (GI) bleeding patients in a large teaching hospital.METHODS: All patients admitted for non-variceal acute upper GI bleeding for over a 2-year period were potentially eligible for this study. They were managed by a team of seven endoscopists on 24-h call whose experience was categorized into two levels (high and low) according to the number of endoscopic hemostatic procedures undertaken before the study. Endoscopic treatment was standardized according to Forrest classification of lesions as well as the subsequent medical therapy. Time of endoscopy was subdivided into two time periods: routine (8 a.m.-5 p.m.) and on-call (5 p.m.-8 a.m.). For each category of experience and time periods rebleeding rate, transfusion requirement, need for surgery, length of hospital stay and mortality we compared. Multivariate analysis was used to discriminate the impact of different variables on the outcomes that were considered.RESULTS: Study population consisted of 272 patients (mean age 67.3 years) with endoscopic stigmata of hemorrhage. The patients were equally distributed among the endoscopists, whereas only 19% of procedures were done out of working hours. Rockall score and Forrest classification at admission did not differ between time periods and degree of experience.Univariate analysis showed that higher endoscopist's experience was associated with significant reduction in rebleeding rate (14% vs 37%), transfusion requirements (1.8±0.6 vs 3.0±1.7 units) as well as surgery (4% vs 10%), but not associated with the length of hospital stay nor mortality. By contrast, outcomes did not significantly differ between the two time periods of endoscopy.On multivariate analysis, endoscopist's experience was independently associated with rebleeding rate and transfusion requirements. Odds ratios for low experienced endoscopist were 4.47 for rebleeding and 6.90 for need of transfusion after the endoscopy.CONCLUSION: Endoscopist's experience is an important independent prognostic factor for non-variceal acute upper GI bleeding. Urgent endoscopy should be undertaken preferentially by a skilled endoscopist as less expert staff tends to underestimate some risk lesions with a negative influence on hemostasis. | Fabrizio Parente Andrea Anderloni Stefano Bargiggia Venerina Imbesi Emilio Trabucchi Cinzia Baratti Silvano Gallus Gabriele Bianchi Porro | 2005 | World Journal of Gastroenterology2005，11，45： | 4 |
| 2 | Coffee Reduces Risk for Hepatocellular Carcinoma: An Updated Meta-Analysis显示文摘 | Francesca Bravi Cristina Bosetti Alessandra Tavani Silvano Gallus Carlo La Vecchia | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 3 |
| 3 | 口服Xa因子直接抑制剂rivaroxaban(BAY 59-7939)治疗近端深静脉血栓:ODIXa-DVT(急性有症状性深静脉血栓患者口服Xa因子直接抑制剂BAY 59-7939)研究显示文摘背景:在对需长期抗凝治疗疾病的处理中,迫切需要一种不必接受监测以调整剂量的安全有效的口服抗凝药。Rivaroxaban(BAY 59-7939)是一种目前正处于临床开发阶段的口服Xa因子直接抑制剂。方法和结果:在近端深静脉血栓患者中进行此项随机。 | Agnelli G. Gallus A. Goldhaber S.Z. 孙凯 | 2007 | 世界核心医学期刊文摘(心脏病学分册)2007，，11： | 3 |
| 4 | Fondaparinux预防老年急性内科患者发生静脉血栓形成的效果与安全性:随机安慰剂对照研究显示文摘目的:观察 Fondaparinux 对具有中高度静脉血栓发生危险的老年急性内科住院患者的抗凝效果与安全性。设计:双盲随机安慰剂对照研究。背景:8个国家的35个中心。参与者:849例≥60岁内科患者,住院原因分别为充血性心力衰竭、慢性肺病合并急性呼吸系统疾患、急性炎症性或感染性疾病,预期至少住院4天以上。干预:2.5 mg Fondaparinux 或安慰剂,每天1次皮下注射,持续6~14天。观察指标:主要指标为静脉血栓形成(治疗后15天内采用双侧静脉造影检查)及有症状的静脉血栓;次要指标为死亡与出血。患者随访时间为1个月。结果:Fondaparinux 治疗组425例患者和安慰剂组414例患者接受了安全性分析(10例未治疗)。644例患者(75.9%)可接受主要指标分析。静脉血栓检出率在 Fondaparinux 治疗组为5.6%(18/321),安慰剂组为10.5%(34/323),相对危险减少46.7%(95% CI 7.7%~69.3%)。安慰剂组5例患者发生有症状的静脉血栓,Fondaparinux治疗组无患者发生有症状的静脉血栓(P=0.029)。两组均有1例(0.2%)患者发生严重出血。随访结束时,安慰剂组、Fondaparinux 治疗组分别死亡25(6.0%)、14(3.3%)例患者。结论:Fondaparinux 可有效预防急性内科老年患者无症状性及有症状的静脉血栓。严重出血几率两组相似。 | Alexander T Cohen Bruce L Davidson Alexander S Gallus Michael R Lassen Martin H Prins Witold Tomkowski Alexander G G Turpie Jan F M Egberts Anthonie W A Lensing 石汉平(译) 王深明(校) | 2006 | 英国医学杂志中文版2006，9，5： | 3 |
| 5 | Glycemic index, glycemic load and risk of gastric cancer显示文摘 | Augustin LS Gallus S Negri E | 2004 | Ann Oncol2004，15，4： | 1 |
| 6 | Apixaban or enoxaparin for thromboprophylaxis after knee replacement 显示文摘 | Lassen MR Raskob GE Gallus A | 2009 | New E J Med2009，361，： | 1 |
| 7 | Treatment of proximal deep- vein thrombosis with the oral direct factor Xa inhibitor rlvarexaban ( BAY 59-7939 ) : the ODIXa-DVT ( Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Throm- bosis ) study 显示文摘 | Agnelli G Gallus A Goldhabcr SZ | 2007 | Circulation2007，116，2： | 1 |
| 8 | Menopause and colorectal cencer显示文摘 | Francesehi 5 Gallus S Talamini R | 2000 | Br J Cancer2000，82，11： | 1 |
| 9 | Hormone replacement therapy and cancer a risk systematic analysis from a network of case-cotrol studies显示文摘 | Femandez E Gallus S Bosetti C | 2003 | Int J Cancer2003，105，： | 1 |
| 10 | Oral anticoagulant therapy : Antithrombotie Therapy and Prevention of Thrombosis,9th ed:Ameri- can College of Chest Physicians Evidence-Based Clinical Practice Guidelines显示文摘 | Ageno W Gallus )iS Wittkowsky A | 2012 | Chest2012，141，2： | 1 |
| 11 | Apixaban versus enoxaparin for thromboprephylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE - 2 and ADVANCE - 3 trials 显示文摘 | RASKOB G E GALLUS A S PINEO G F | 2012 | J Bone Joint Surg Br2012，94，2： | 1 |
| 12 | Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis显示文摘 | Baker RI Coughlin PB Gallus AS | 2004 | Med J Aust2004，181，9： | 1 |
| 13 | Aspirin use and pancreatic cancer risk显示文摘 | BONIFAZI M GALLUS S BOSETTI C | 2010 | Eur J Cancer Prey2010，19，5： | 1 |
| 14 | Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys:A pooled analysis显示文摘 | Clifford GM Gallus S H errero R | 2005 | Lancet2005，366，9490： | 1 |
| 15 | Warfarin reversal: consensus guidelines, on be- half of the Australasian Society of Thrombosis and Haemostasis显示文摘 | BAKER R I COUGHLIN P B GALLUS A S | 2004 | Med J Aust2004，181，： | 1 |
| 16 | Apixaban or enoxaparin for thromboprophylaxis after knee replacement 显示文摘 | Lassen MR Raskob GE Gallus A | 2009 | N Engl J Med2009，361，： | 1 |
| 17 | Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients:randomised placebo controlled trial显示文摘 | Cohen AT Davidson BL Gallus AS | | 0，，7537： | 1 |
| 18 | Nutrition and cancer risk: an overview显示文摘 | Fernandez E Gallus S La Vecchia C | 2006 | J Br Menopause Soc2006，12，4： | 1 |
| 19 | Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE - 2 ) : a randomised double - blind trial 显示文摘 | Lassen MR Raskob GE Gallus A | 2010 | Lancet2010，375，： | 1 |
| 20 | Nutrition and cancer risk:an overview显示文摘 | Fernandez E Gallus S La Vecchia C | 2006 | J Br Menopause Soc2006，12，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员